Core Viewpoint - Samsung Bioepis has commenced the direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe [1] Company Summary - Samsung Bioepis is actively entering the European market with its biosimilar product BYOOVIZ® [1]

Group 1 - Samsung Bioepis' Byooviz PFS has received European approval, marking a significant milestone for the company in the biopharmaceutical sector [1] - This approval is expected to enhance Samsung Bioepis' position in the biosimilar market, particularly in Europe [1] - The company aims to leverage this approval to expand its product offerings and increase market share in the competitive landscape of biologics [1]